reports
- Mariem Ben Nejma
- Sinan Doganli
- Mariem Ben Nejma
- Sinan Doganli
- Christophe Chaput
- Christophe Chaput
Pharming Group announces 2026 financial guidance and highlights rare d...
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:...
Pharming Group receives Complete Response Letter from U.S. FDA for sND...
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rar...
WINFARM : Growth of +9.2% in Q4 2025. 2025 revenue of €146.2m, up +6.1...
WINFARM : Growth of +9.2% in Q4 2025. 2025 revenue of €146.2m, up +6.1%. PRESS RELEASE Loudéac, 29 January 2026 Growth of +9.2% in Q4 2025 2025 revenue of €146.2m, up +6.1% WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in distance-selling of products and solutions for the agricultural and livestock industry, is today publishing its revenue for the fourth quarter of 2025 and for full-year 2025. WINFARM made consolidated revenue of €35.7 million in Q4 2025, an increase of +9.2% versus Q4 2024, representing a seventh consecutive quarter of growth. This perform...
WINFARM : Croissance de +9,2% au 4 è trimestre 2025. Chiffre d’affaire...
WINFARM : Croissance de +9,2% au 4 è trimestre 2025. Chiffre d’affaires 2025 de 146,2 M€, en hausse de +6,1%. COMMUNIQUE DE PRESSE Loudéac, 29 janvier 2026 Croissance de +9,2% au 4è trimestre 2025 Chiffre d’affaires 2025 de 146,2 M€, en hausse de +6,1% WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce ce jour la publication du chiffre d’affaires du 4e trimestre 2025 et en cumul sur l’exercice 2025. Au 4è trimestre 2025, WINFARM enregistre un chiffre d'affaires consolidé de 35,7 M€, en hausse de +9,2% par rapport au...
WINFARM : Calendrier de communication financière 2026.
WINFARM : Calendrier de communication financière 2026. COMMUNIQUE DE PRESSE Loudéac, le 13 janvier 2026 Calendrier de communication financière 2026 WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, publie aujourd’hui son calendrier financier pour l’exercice 2026. DATES DE PUBLICATION 2026 CHIFFRE D’AFFAIRES ANNUEL 2025 Jeudi 29 janvier 2026, après Bourse RESULTATS ANNUELS 2025 Mardi 31 mars 2026, après Bourse CHIFF...
Pharming Group reports preliminary 2025 revenues and announces Investo...
Pharming Group reports preliminary 2025 revenues and announces Investor Day Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET). Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2...
Pharming Group NV: 1 director
A director at Pharming Group NV sold 90,691 shares at 1.500EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Pharming Group reports third quarter 2025 financial results with signi...
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for c...
WINFARM : Revenue growth of +5.1% to 30 September 2025.
WINFARM : Revenue growth of +5.1% to 30 September 2025. PRESS RELEASE Loudéac, 5 November 2025 Revenue growth of +5.1% to 30 September 2025 WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in distance-selling of products and solutions for the agricultural and livestock industry, is today reporting its revenue for the third quarter of 2025 and for the first nine months of 2025. in €m, unauditedQ3 2024Q3 2025Chg. 9M 20249M 2025Chg.Farming Supplies30.131.2+3.8% 92.896.4+3.9%Farming Production4.33.9-9.9% 10.612.1+13.9%Other10.70.9+27.7% 1.72.1+17.2%TOTAL35.136.0+2.6%...
WINFARM : Croissance de +5,1% du chiffre d’affaires au 30 septembre 20...
WINFARM : Croissance de +5,1% du chiffre d’affaires au 30 septembre 2025. COMMUNIQUE DE PRESSE Loudéac, 5 novembre 2025 Croissance de +5,1% du chiffre d’affaires au 30 septembre 2025 WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce ce jour la publication du chiffre d’affaires du troisième trimestre 2025 et en cumul sur les neuf premiers mois de l’exercice 2025. En M€, non auditéT3 2024T3 2025VAR 9 mois 20249 mois 2025VARAgroFourniture30,131,2+3,8% 92,896,4+3,9%AgroProduction4,33,9-9,9% 10,612,1+13,9%Autres10,70,9+27...
- Juan Ros-Padilla
- Thomas Zlowodzki
SSAB A SSAB AB CLASS A
BEN BENETEAU SA
ALDEL DELFINGEN INDUSTRY SA
WHA WERELDHAVE N.V.
OERL OC OERLIKON CORPORATION AG
ELG ELMOS SEMICONDUCTOR SE
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
NEX NEXANS SA
COR CORTICEIRA AMORIM SGPS SA
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BCHN BURCKHARDT COMPRESSION HOLDING AG
B7E BLUE CAP
COFA COFACE SA
ATRY ATRYS HEALTH
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
- Juan Ros-Padilla
- Thomas Zlowodzki
SSAB A SSAB AB CLASS A
BEN BENETEAU SA
ALDEL DELFINGEN INDUSTRY SA
WHA WERELDHAVE N.V.
OERL OC OERLIKON CORPORATION AG
ELG ELMOS SEMICONDUCTOR SE
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
NEX NEXANS SA
COR CORTICEIRA AMORIM SGPS SA
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BCHN BURCKHARDT COMPRESSION HOLDING AG
B7E BLUE CAP
COFA COFACE SA
ATRY ATRYS HEALTH
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
- Christophe Chaput
- Christophe Chaput
WINFARM : Modalités de mise à disposition du Rapport Financier Semestr...
WINFARM : Modalités de mise à disposition du Rapport Financier Semestriel 2025. COMMUNIQUE DE PRESSE Loudéac, le 28 octobre 2025 MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025 WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce que son rapport financier semestriel 2025 a été déposé auprès de l’Autorité des Marchés Financiers (AMF), le 28 octobre 2025. Ce document est disponible sur le site de la Société à l’adresse -group.com et sur le site de l’AMF (-france.org). Il est également tenu à disp...
Pharming Group announces presentations at 2025 ACAAI Annual Scientific...
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10. Five posters will present positive new clinical, economic, and comparative data for RUCONEST® (recombinant C1 esterase inhibi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.